
Personalized medicine
Personalized healthcare solutions require an integrative, systems approach to understanding human biocomplexity. Microbiome research is a key component of this approach (Nicholson, 2006) (Box 2-1). Genes are just one component of the interaction of genes, diet and microbes that make humans the “supersystem” that they are. So while genome-wide association studies (GWAS), for example, are very popular, they are not always, in Jeremy Nicholson’s words, “extremely revealing” because statistical significance often has very little to do with biological significance.
This does not mean that studies of the complexity of the human genome at the systems level do not provide interesting information. They are. For example, Loscalzo et al. (2007) used a systems-level approach to show that almost all human diseases are genetically linked, with the same gene(s) implicated in different disorders. However, understanding the human genome per se is not enough to realize the concept of personalized or “precision” healthcare (Mirnezami et al., 2012). The microbiome represents another level of genetic connection. The challenge for the future is to “think about layers of networks on top of networks.” That is, how does the human genome network interact with the microbiome genome network both in time and space? It’s really quite a difficult problem, probably the most difficult problem in biology of the 21st century.
One of the goals of a systematic understanding of human biocomplexity is the implementation of the concept of personalized or “precision” health care (Mirnezami et al., 2012). Pharmaceutical metabonomics is one component of this concern. Pharmacetabonomics as “prediction of the quantitative outcome or effect of a biomedical intervention based on a pre-treatment metabolic model.” The approach is based on the concept of “metabolic hyperspace”, where a person’s position depends on many factors (genes, diet, microbiome) (Nicholson and Wilson, 2003). The closer two people are in metabolic hyperspace, the more physiologically similar they are and the more likely they are to behave similarly when faced with a problem (such as a drug or other therapeutic intervention). As an example of potential pharmacobonomic applications, Clayton et al. (2006) demonstrated that drug toxicity could be predicted based on preintervention urinary metabolic profiles.
In addition to drug toxicity, preintervention metabolic profiling has also been used to predict drug metabolism. For example, Clayton et al. (2009) demonstrated a link between gut microbial metabolites and acetaminophen (Tylenol) metabolism, with patterns of microbial excretion partly determining whether an individual is low or high sulfate. Sulfation is one of the two major pathways of acetaminophen metabolism, with weak sulfates being poor metabolizers. Nicholson explained that clostridia and other microbes produce 4-cresol, a structural analogue of acetaminophen, which saturates the sulfation system to form a weak sulfate. Moreover, 4-cresol competes for sulfation not only with acetaminophen, but also with all hydroxylated drugs. Nicholson said: “It affects hundreds of different compounds. One gut microbial enzyme actually has a surprising effect on metabolic patterns and is potentially toxic to a very large number of drugs.”
Interestingly, children with autism cannot sulfate acetaminophen (Alberti et al., 1999). In fact, the ability to sulfate acetaminophen is one of the most statistically significant tests for autism. Again, there is evidence of a microbial connection. Finegood et al (2002) demonstrated abnormal clostridia in children with autism. Altieri et al. (2011) showed that children with autism have much higher levels of microbial cresol than normal children.
Recommended Products

Contacts
Head office of the company
BIODONATUM TRADING
Dubai, United Arab Emirates, Dubai Silicon Oasis, DDP, Building A1





